MedWorm: Actonel

Three-Year Experience with Risedronate Therapy for Patients with an Increased Fracture Risk: Assessment of Proximal Femoral Bone Density and Geometry by DXA

Clinical Drug Investigation — Fri, 13 Jan 2012 23:22:39 +0100

(Source: Clinical Drug Investigation)

MedWorm Sponsor Message: Find the best January Sales in the UK.

A study of changes in bone metabolism in cases of gender identity disorder

Journal of Bone and Mineral Metabolism — Fri, 06 Jan 2012 06:43:44 +0100

Abstract The aim of this study was to determine the effect of increasing estrogen and decreasing androgen in males and increasing androgen and decreasing estrogen in females on bone metabolism in patients with gender identity disorder (GID). We measured and examined bone mineral density (BMD) and bone metabolism markers retrospectively in GID patients who were treated in our hospital. In addition, we studied the effects of treatment on those who had osteoporosis. Patients who underwent a change from male to female (MtF) showed inhibition of bone resorption and increased L2–4 BMD whereas those who underwent a change from female to male (FtM) had increased bone resorption and decreased L2–4 BMD. Six months after administration of risedronate to FtM patients with osteopor...

A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?

Irish Journal of Medical Science — Thu, 05 Jan 2012 17:07:28 +0100

Conclusion The CTX test was not predictive for the development of BRONJ following oral surgery. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s11845-011-0790-5Authors J. E. O’Connell, Department of Oral and Maxillofacial Surgery, St James’s Hospital, Dublin 8, IrelandO. Ikeagwani, Oral Surgeon, Cahercalla, Ennis, Clare, IrelandG. J. Kearns, Department of Oral and Maxillofacial Surgery, St James’s Hospital, Dublin 8, Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)

Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

Bone — Wed, 28 Dec 2011 20:53:30 +0100

We examined the changes of femoral and trabecular bone morphologies after treatment. ► All mice showed powerful anti-osteoporosis effects in all parameters. ► No skin irritation was occurred in all groups of ovariectomized mouse after administration of risedronate. (Source: Bone)

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Bone — Wed, 28 Dec 2011 20:53:30 +0100

Abstract: Background: We studied 265 men (mean age 56.4years; range 18–83years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).Methods: Patients received either a single ZOL 5mg infusion or RIS 5mg oral daily at randomization, along with calcium (1000mg) and vitamin D (400–1200IU). Primary endpoint: difference in percentage change from baseline in bone mineral density (BMD) at the lumbar spine (LS) at 12months. Secondary endpoints: percentage changes in BMD at total hip (TH) and femoral neck (FN), relative changes in bone turnover markers (β-CTx...

Actonel and Dental Implants: What is the proper protocol?

Dental Implants Discussed by Experts — Mon, 26 Dec 2011 02:32:27 +0100

How long should I wait after she stops the Actonel before I place the dental implants? (Source: Dental Implants Discussed by Experts)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): Small but increased risk of unusual thigh bone fractures

Government of Canada News - Health Canada — Mon, 19 Dec 2011 20:00:00 +0100

Health Canada is updating Canadians with respect to its review of bisphosphonate drugs, used to treat osteoporosis, and the risk of a rare but serious type of thigh bone fracture known as an "atypical femur fracture." (Source: Government of Canada News - Health Canada)

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer

Journal of Bone and Mineral Metabolism — Mon, 12 Dec 2011 17:14:26 +0100

In conclusion, anastrozole treatment for EBC in elderly women seems to have only mild negative effects on the femoral bone. Risedronate makes the use of anastrozole safer, even for osteopenic or osteoporotic elderly patients. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00774-011-0341-1Authors Giuseppe Sergi, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyGiulia Pintore, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyCristina Falci, Istituto Oncologico Veneto (IOV), IRCCS, Padua, ItalyNicola Veronese, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyLinda Berton, Department of Medical and Surgical Sciences, University of Padova, Padua, ItalyEgle Perissinotto,...

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures

Osteoporosis International — Mon, 12 Dec 2011 17:13:25 +0100

Conclusions Although there were no differences in back pain-related endpoints, patients receiving teriparatide had greater skeletal benefit than those receiving risedronate. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1856-yAuthors P. Hadji, Department of Endocrinology, Osteoporosis, and Reproductive Medicine, Philipps-University of Marburg, Marburg, GermanyJ. R. Zanchetta, IDIM, Buenos Aires, ArgentinaL. Russo, CCBR Brazil Clinical Research Center, Rio de Janeiro, BrazilC. P. Recknor, United Osteoporosis Centers, Gainesville, GA, USAK. G. Saag, University of Alabama, Birmingham, AL, USAF. E. McKiernan, Center for Bone Disease, Marshfield Clinic, Marshfield, WI, USAS. L. Silverman, Cedars-Sinai/UCLA and OMC Clinical Research ...

Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: Role of the akt pathway and the ERK/Bim axis

Arthritis and Rheumatism — Thu, 01 Dec 2011 05:00:00 +0100

ConclusionOur findings indicate that the antiresorptive effect of risedronate in vivo is mainly mediated by the suppression of the bone‐resorbing activity of osteoclasts and not by the induction of osteoclast apoptosis. (Source: Arthritis and Rheumatism)

The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

Orthopedics — Thu, 01 Dec 2011 05:00:00 +0100

Authors: PMID: 22147217 [PubMed - in process] (Source: Orthopedics)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The association between automatic generic substitution and treatment persistence with oral bisphosphonates

Osteoporosis International — Sat, 26 Nov 2011 06:40:11 +0100

Conclusion AGS causes increased product substitution which appears to be associated with reduced treatment persistence. Poor health outcomes and associated costs due to forgone drug exposure should be taken into account in the design and evaluation of policies implemented to encourage utilisation of generic medicines. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00198-011-1850-4Authors O. Ström, Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Berzelius väg 3, 171 77 Stockholm, SwedenE. Landfeldt, OptumInsight, Stockholm, Sweden Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Impact of Medication Adherence on Health Care Utilization and Productivity: Self-Reported Data From a Cohort of Postmenopausal Women on Osteoporosis Therapy.

Clinical Therapeutics — Wed, 16 Nov 2011 05:00:00 +0100

CONCLUSIONS: Use of diagnostic testing differed significantly by osteoporosis treatment status. Compared with women who persisted with treatment, primary care provider visits were less common among those who discontinued treatment. Treatment persistence was not associated with significant differences in productivity measures. PMID: 22099387 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw

Journal of Bone and Mineral Metabolism — Mon, 07 Nov 2011 17:12:25 +0100

In conclusion, at the moment insufficient data are available to prove a greater risk of ONJ in children with OI than in children affected by other forms of bone fragility. However, cases may emerge in future because the risk of ONJ seems to be related to the cumulative dose and the duration of therapy. Content Type Journal ArticleCategory Original ArticlePages 1-5DOI 10.1007/s00774-011-0331-3Authors Evelina Maines, Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital “Giambattista Rossi”, Piazzale Ludovico Antonio Scuro 10, 37134 Verona, ItalyElena Monti, Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital “Giambattista Rossi”, Piazzale Ludovico Antonio Sc...

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial

Journal of Neurology, Neurosurgery and Psychiatry — Mon, 07 Nov 2011 05:00:00 +0100

Conclusions Treatment with once-weekly risedronate and ergocalciferol prevents hip fractures in older women with PD. (Source: Journal of Neurology, Neurosurgery and Psychiatry)

Treatment of osteoporosis in women intolerant of oral bisphosphonates

Maturitas — Mon, 31 Oct 2011 04:00:00 +0100

Abstract: In the past 15 years, oral bisphosphonate therapy has become the mainstay of pharmacological management in patients with osteoporosis. In the UK, alendronate is the drug of first choice, based on clinical efficacy data and cost. However, some patients are unable to take oral bisphosphonates for a number of reasons. In this article, we review the practical management of such cases, including strategies for monitoring adherence and switching to alternative oral agents (e.g. risedronate, strontium ranelate, raloxifene). In some cases, alternative parenteral agents may be considered, including intravenous bisphosphonates, parathyroid hormone therapies and denosumab. Specific concerns about safe prescribing are considered, when prescribing potent anti-resorptive medications, particula...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Risedronate Decreases Bone Loss Around Hip Implants, But How Useful Is Its Effect?: Commentary on an article by Olof Gustaf Sköldenberg, MD, PhD, et al.: "The Effect of Weekly Risedronate on Periprosthetic Bone Resorption Following Total Hip Arthroplasty. A Randomized, Double-Blind, Placebo-Controlled Trial".

The Journal of Bone and Joint Surgery. American volume — Wed, 19 Oct 2011 04:00:00 +0100

Risedronate Decreases Bone Loss Around Hip Implants, But How Useful Is Its Effect?: Commentary on an article by Olof Gustaf Sköldenberg, MD, PhD, et al.: "The Effect of Weekly Risedronate on Periprosthetic Bone Resorption Following Total Hip Arthroplasty. A Randomized, Double-Blind, Placebo-Controlled Trial". J Bone Joint Surg Am. 2011 Oct 19;93(20):e1201-2 Authors: Hamilton WG PMID: 22012537 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)

The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

The Journal of Bone and Joint Surgery. American volume — Wed, 19 Oct 2011 04:00:00 +0100

Conclusions:Risedronate taken once weekly for six months following total hip arthroplasty was effective in reducing periprosthetic bone resorption around an uncemented femoral stem up to one year after surgery but had no discernible effect on implant migration or clinical outcome. Future studies of bisphosphonate treatment following total hip arthroplasty should focus on clinically relevant end points such as the risks of fracture and revision arthroplasty.Level of Evidence:Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence. PMID: 22012522 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)

Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women

Osteoporosis International — Sat, 08 Oct 2011 05:51:51 +0100

Conclusions Bone metabolism at the spine remained suppressed following treatment discontinuation. A significant increase in SUV at the femoral shaft and total hip after 12 months was observed but for the ALN group only. This study was small, and further clinical studies are required to fully evaluate the persistence of BP treatment. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1805-9Authors M. L. Frost, Osteoporosis Research Unit, King’s College London, Guy’s Hospital Campus, Great Maze Pond, London, SE1 9RT UKM. Siddique, Osteoporosis Research Unit, King’s College London, Guy’s Hospital Campus, Great Maze Pond, London, SE1 9RT UKG. M. Blake, Osteoporosis Research Unit, King’s College London, Guy’s Hospital C...

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

Osteoporosis International — Thu, 06 Oct 2011 06:28:46 +0100

Conclusions This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00198-011-1800-1Authors C. Roux, Rheumatology Department, Paris Descartes University, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75679 Paris cedex 14, FranceD. M. Reid, University of Aberdeen, Aberdeen, UKJ.-P. Devogelaer, Universite Catholique de Louvain, Brussels, BelgiumK. Saag, University of Alabama at Birmingham, Birmingham, AL, USAC. S. Lau, University of Hong Kong, Hong Kong, People’s Republic of ChinaJ.-Y. Reginster, University of Liege, Liege, Be...

Use of bisphosphonates in pregnancy

NeLM - Drugs in Pregnancy — Tue, 04 Oct 2011 04:00:00 +0100

Source: UK Teratology Information Service Area: Evidence > Drugs in Pregnancy SUMMARY: The bisphosphonates are a class of drugs prescribed to prevent the loss of bone mass. They are used to treat osteoporosis (both idiopathic and glucocorticoid-induced), Paget's disease of the bone, and skeletal pain associated with metastatic breast cancer. There are currently eight bisphosphonates available in the UK: alendronic acid, disodium etidronate, disodium pamidronate, ibandronic acid, risedronate sodium, sodium clodronate, tiludronic acid and zoledronic acid. In rats, bisphosphonates are incorporated into fetal bones, affecting bone growth. This may also be a concern in human pregnancy, particularly as bisphosphonates are incorporated into the maternal bone and may ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Osteoporosis International — Tue, 27 Sep 2011 05:48:42 +0100

Conclusions Risedronate 35 mg DR weekly is similar in efficacy and safety to risedronate 5 mg IR daily, and will allow patients to take their weekly risedronate dose immediately after breakfast. Content Type Journal ArticleCategory Original ArticlePages 1-10DOI 10.1007/s00198-011-1791-yAuthors M. R. McClung, Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USAP. D. Miller, Colorado Center for Bone Research, Lakewood, CO, USAJ. P. Brown, Groupe de recherche en rhumatologie et maladies osseuses, Québec, QC, CanadaJ. Zanchetta, University of El Salvador, Metabolic Research Institute, Buenos Aires, ArgentinaM. A. Bolognese, Bethesda Health Research, Bethesda, MD, USAC. L. Benhamou, Institut de Prévention et de Recherche sur l’Ostéop...

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

BMC Musculoskeletal Disorders — Mon, 26 Sep 2011 04:00:00 +0100

Conclusion: Teriparatide, zoledronic acid and denosumab have the highest probabilities of being most efficacious for non-vertebral and vertebral fractures, and having the greatest effect sizes. The estimates from indirect comparisons were robust to differences in methodology. (Source: BMC Musculoskeletal Disorders)

Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

Bone — Mon, 19 Sep 2011 04:00:00 +0100

Abstract: In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a dire...

F.D.A. Panels Back Sterner Language on Bone Drugs

NYT Health — Sat, 10 Sep 2011 04:27:27 +0100

The F.D.A. is expected to issue a revised label in November for bone-building drugs like Fosamax, Actonel and Boniva. (Source: NYT Health)

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage

Osteoporosis International — Thu, 08 Sep 2011 05:55:48 +0100

Conclusions Oral bisphosphonates are the primary drugs used to treat osteoporosis in Canada. Prescribing practices changed over time as newer medications came to market, yet access to second-generation bisphosphonates through BC PharmaCare was limited. Implications of differential access to oral bisphosphonates warrants further study. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00198-011-1771-2Authors S. M. Cadarette, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, M5S 3M2 ON, CanadaG. Carney, Therapeutics Initiative, University of British Columbia, Victoria, BC, CanadaD. Baek, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, M5S 3M2 ON, CanadaN. Gunraj, Institute f...

Distinguishing the pro‐apoptotic and anti‐resorptive functions of risedronate in osteoclasts: Role of the Akt pathway and the Erk/Bim axis

Arthritis and Rheumatism — Thu, 25 Aug 2011 23:00:00 +0100

Conclusion.Our findings indicate that the anti‐resorptive effect of RIS in vivo is mainly mediated by the suppression of the bone‐resorbing activity of OCs, not the induction of OC apoptosis. (Source: Arthritis and Rheumatism)

Actonel (risedronate) May Be Tied to Lower Colon Cancer RiskActonel (risedronate) May Be Tied to Lower Colon Cancer Risk

Medscape Gastroenterology Headlines — Wed, 24 Aug 2011 00:34:27 +0100

A new study adds to evidence that bisphosphonates may play a role in suppressing cancer development, although there is still no firm proof. Reuters Health Information (Source: Medscape Gastroenterology Headlines)

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover.

The Journal of Clinical Endocrinology and Metabolism — Tue, 23 Aug 2011 23:00:00 +0100

Conclusions: One year of discontinuation of risedronate treatment in patients who had received 2 or 7 yr of risedronate therapy led to increases in NTX/Cr levels toward baseline and decreases in femoral trochanter and total hip BMD. PMID: 21865359 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

Journal of Cystic Fibrosis — Mon, 22 Aug 2011 04:00:00 +0100

Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo. (Source: Journal of Cystic Fibrosis)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Elevated International Normalized Ratio Associated with Use of Dronedarone and Warfarin (September).

The Annals of Pharmacotherapy — Mon, 01 Aug 2011 23:00:00 +0100

CONCLUSIONS: Clinicians should monitor patients who are taking warfarin and dronedarone for INR changes and bleeding episodes about 1 week after initiation of dronedarone. If a significant interaction is noted, the warfarin dosage should be decreased and the patient should be monitored within 2 weeks to assess the need for further adjustments. PMID: 21811004 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan

Journal of Evaluation in Clinical Practice — Mon, 01 Aug 2011 04:00:00 +0100

Conclusions Osteoporosis treatment change occurred in approximately 12% of members, while a greater proportion of members discontinued treatment completely within 12 months. Member characteristics may be used to predict therapy change for evaluation and quality initiatives within a health plan. (Source: Journal of Evaluation in Clinical Practice)

[Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios].

Reumatismo — Sun, 31 Jul 2011 15:00:21 +0100

Authors: Di Munno O, Delle Sedie A Osteoporosis (OP) and increased risk of fracture (Fx) associated with chronic glucocorticoid treatment pushed panels of experts and scientific societies to produce recommendations for both prevention and treatment of glucocorticoid-induced OP (GIO). Recently the American College of Rheumatology developed and/or endorsed their updated guidelines and recommendations for the prevention and treatment of GIO. In these recommendations the use of FRAX tool, for the 10-year probability of a major osteoporotic Fx, was integrated with other clinical risk factors to define low-, medium-, and high-risk patients. Updated approaches are delineated for post-menopausal women and men >50 years, pre-menopausal women not of childbearing potential, men <50 years an...

Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover

Bone — Tue, 26 Jul 2011 23:00:00 +0100

This study evaluated the urinary excretion of alendronate and risedronate in patients treated with these drugs for osteoporosis and analysed its relationship with bone turnover, time of previous drug exposure and time of treatment discontinuation. We included 43 women (aged 65±9.4years) previously treated with alendronate (36) or risedronate (7) during a mean of 51±3 and 53±3months, respectively, who had not been treated with other antiosteoporotic treatment and with a median time of discontinuation of 13.5 and 14months, respectively. Both BP were detected in 24-hour urine by HPLC. In addition, bone formation (PINP) and resorption (NTx) markers were analysed. Both BP were also determined in a control group of women during treatment. Alendronate was detected in 41% of women previously tr...

FDA MedWatch - Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer

Drugs.com - Pharma News — Thu, 21 Jul 2011 19:07:05 +0100

Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) AUDIENCE: Geriatrics, Family Practice, Internal Medicine ISSUE: FDA notified... (Source: Drugs.com - Pharma News)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer

Drugs.com - FDA MedWatch Alerts — Thu, 21 Jul 2011 04:00:00 +0100

Audience: Geriatrics, Family Practice, Internal Medicine Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified... (Source: Drugs.com - FDA MedWatch Alerts)

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

Osteoporosis International — Fri, 08 Jul 2011 06:38:02 +0100

Conclusions Risedronate in adults with OI type I results in modest but significant increases in BMD at LS, and decreased bone turnover. However, this may be insufficient to make a clinically significant difference to fracture incidence. Content Type Journal ArticlePages 1-10DOI 10.1007/s00198-011-1658-2Authors L. A. Bradbury, University of Queensland Diamantina Institute, University of Queensland, Brisbane, AustraliaS. Barlow, Nuffield Orthopaedic Centre NHS Trust, Oxford, UKF. Geoghegan, Ealing Hospital NHS Trust, Oxford, UKR. A. Hannon, Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UKS. L. Stuckey, Monash University, Melbourne, AustraliaJ. A. H. Wass, Nuffield Orthopaedic Centre NHS Trust, Oxford, UKR. G. G. Russell, Nuffield Department of O...

Bisphosphonates do not alter the rate of secondary mineralization

Bone — Wed, 06 Jul 2011 23:00:00 +0100

Abstract: Bisphosphonates function to reduce bone turnover, which consequently increases the mean degree of tissue mineralization at an organ level. However, it is not clear if bisphosphonates alter the length of time required for an individual bone-modeling unit (BMU) to fully mineralize. We have recently demonstrated that it takes ~350days (d) for normal, untreated cortical bone to fully mineralize. The aim of this study was to determine the rate at which newly formed trabecular BMUs become fully mineralized in rabbits treated for up to 414d with clinical doses of either risedronate (RIS) or alendronate (ALN). Thirty-six, 4-month old virgin female New Zealand white rabbits were allocated to RIS (n=12; 2.4μg/kg body weight), ALN (n=12; 2.4μg/kg body weight), or volume-matched saline con...

Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (SARA)

Calcified Tissue International — Wed, 22 Jun 2011 06:07:20 +0100

In conclusion, no significant difference in the incidence of GIAEs was found between patients prescribed alendronate, risedronate, and strontium ranelate. Individuals prescribed raloxifene had a significantly lower risk of GIAEs compared with patients prescribed alendronate. No significant difference was found in the frequency of hospitalization for GIAEs. Switching between osteoporosis medications and drug classes was uncommon. Prescribers should consider the real-world gastrointestinal safety of osteoporosis drugs when choosing between treatment options to potentially improve medication adherence and consequently effectiveness. Content Type Journal ArticlePages 1-12DOI 10.1007/s00223-011-9511-3Authors Erik Landfeldt, Innovus, Stockholm, SwedenAndrea Lang, Innovus, Stockholm, ...

Physiology of the aging bone and mechanisms of action of bisphosphonates.

Biogerontology — Tue, 21 Jun 2011 23:00:00 +0100

Authors: Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M Fragility fractures, a major public health concern, are expected to further increase due to aging of the world populations because age remains a cardinal, independent determinant of fracture risk. With aging the balance between bone formation and resorption during the remodeling process becomes negative, with increased resorption and reduced formation. Bisphosphonates (BPs) are widely prescribed anti-resorptive agents that inhibit osteoclasts attachment to bone matrix and enhance osteoclast apoptosis. BPs can be divided into nitrogen-containing (N-BPs) and non-nitrogen-containing BPs (non-N-BPs). Both classes induce apoptosis but they evoke it differently. Several studies have examined the molecular mechanisms underlying BPs'...

MedWorm Sponsor Message: Find the best January Sales in the UK.

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 09 Jun 2011 05:00:00 +0100

Updated Date: Jun 9, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months

Calcified Tissue International — Fri, 27 May 2011 18:12:03 +0100

The objective of this 18-month prospective study was to investigate the effect of teriparatide [rhPTH(1–34)] in 25 female osteoporotics who were inadequate responders to oral bisphosphonates and to correlate microarchitectural changes in three consecutive iliac crest biopsies measured by micro-computed tomography (μCT) with bone mineral density (BMD) and bone serum markers. Scanned biopsies at baseline (M0), 6 months (M6), and 18 months (M18) demonstrated early significant (P < 0.01) increases in bone volume per tissue volume (+34%) and trabecular number (+14%) at M6 with only moderate changes in most μCT structural parameters between M6 and M18. μCT-measured bone tissue density was significantly decreased at M18, expressing an overall lower degree of tissu...

Resolved Recurrent Bilateral Anterior Uveitis With Discontinuation of Bisphosphonate

Optometry - Journal of the American Optometric Association — Fri, 27 May 2011 16:06:06 +0100

Bisphosphonates such as ibandronate, alendronate, and risedronate are commonly used in postmenopausal women to treat osteoporosis. There are ocular complications associated with the use of bisphosphonates including uveitis, iritis, scleritis, and conjunctivitis. Ocular incidence range from 0.046% to 1%. The symptoms usually improve and are reversible with discontinuation of the medication, but recurrent ocular inflammation and affected and contralateral eye involvement often lasts up to 1 year. (Source: Optometry - Journal of the American Optometric Association)

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott (US), LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 May 2011 05:00:00 +0100

Updated Date: May 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Assessment of Regional Skeletal Metabolism: Studies of Osteoporosis Treatments Using Quantitative Radionuclide Imaging

Journal of Clinical Densitometry — Tue, 24 May 2011 23:00:00 +0100

Abstract: Studies of bone remodeling using bone biopsy and biochemical markers of bone turnover play an important role in research studies to investigate the effect of new osteoporosis treatments on bone quality. Quantitative radionuclide imaging using either positron emission tomography with fluorine-18 sodium fluoride or gamma camera studies with technetium-99m methylene diphosphonate provides a novel tool for studying bone metabolism that complements conventional methods, such as bone turnover markers (BTMs). Unlike BTMs, which measure the integrated response to treatment across the whole skeleton, radionuclide imaging can distinguish the changes occurring at sites of particular clinical interest, such as the spine or proximal femur. Radionuclide imaging can be used to measure either bo...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bisphosphonate treatment delays stress fracture remodeling in the rat ulna

Journal of Orthopaedic Research — Fri, 20 May 2011 20:51:35 +0100

In conclusion, high dose bisphosphonate treatment impaired healing of a large stress fracture line by reducing the volume of bone resorbed and replaced during remodeling. We also confirmed that periosteal callus formation was not adversely affected by risedronate treatment. © 2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res (Source: Journal of Orthopaedic Research)

Bisphosphonates: The first 40years

Bone — Thu, 19 May 2011 23:00:00 +0100

This article is part of a Special Issue entitled Bisphosphonates.Research highlights: ► The biological effects of bisphosphonates (BPs) were first published in 1969. ► The potency of BPs on bone resorption depends on binding to bone mineral and osteoclast inhibition. ► Nitrogen-BPs inhibit farnesyl pyrophosphate synthase(FPPS) and protein prenylation. ► BPs are the major drugs for treating Paget’s disease, bone metastases, and osteoporosis. ► Knowledge of structure-activity enables rational design of new BP drugs. (Source: Bone)

Risedronate and low-dose testosterone help BMI in anorexia nervosa

Modern Medicine — Thu, 12 May 2011 23:00:00 +0100

NEW YORK (Reuters Health) - For women with anorexia nervosa, weekly risedronate increases spinal bone mineral density. Adding low-dose testosterone does not improve BMD further but does increase lean body mass, a Boston team reports. (Source: Modern Medicine)

The relationship between the chemistry and biological activity of the bisphosphonates

Bone — Sun, 08 May 2011 23:00:00 +0100

This article is part of a Special Issue entitled Bisphosphonates.Research Highlights: ► Understanding how bisphosphonates (BPs) work has progressed to a more rational basis. ► Bisphosphonate-farnesyl pyrophosphate synthase(FPPS) complexes can be co-crystallized. ► Antiresorptive activity of N-BPs depends on mineral binding and FPPS inhibition. ► Fluorescent probes are providing new information on bisphosphonate localization. ► New knowledge of structure-activity enables rational design of bisphosphonate drugs. (Source: Bone)

Review: Vertebral Fractures

NeLM - News — Wed, 27 Apr 2011 23:00:00 +0100

Source: N Engl J Med Area: News This review in the New England Journal of Medicine on vertebral fractures begins with a case vignette followed by a discussion of the following topics, ending with the author's clinical recommendations on the management of the case in hand: . Evaluation . Bone mineral density . Diagnosis . Treatment - pain management, rehabilitation, vertebroplasty and kyphoplasty, calcium and vitamin D, pharmacotherapy (alendronate, ibandronate, risedronate, zoledronic acid, bazedoxifene, lasofoxifene, raloxifene, parathyroid hormone, denosumab, strontium ranelate, calcitonin, teriparatide) . Areas of uncertainty . Guidelines from professional societies (Source: NeLM - News)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Effects of Risedronate and Low-Dose Transdermal Testosterone on Bone Mineral Density in Women with Anorexia Nervosa: A Randomized, Placebo-Controlled Study.

The Journal of Clinical Endocrinology and Metabolism — Tue, 26 Apr 2011 23:00:00 +0100

Conclusions: Risedronate administration for 1 yr increased spinal BMD, the primary site of bone loss in women with anorexia nervosa. Low-dose testosterone did not change BMD but increased lean body mass. PMID: 21525157 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice

Bone — Thu, 21 Apr 2011 23:00:00 +0100

In conclusion, the response to mechanical loading in both trabecular and cortical bone in mice is therefore not impaired by short-term treatment with risedronate, even over a 1000-fold dose range. In considering the optimization of treatments for osteoporosis, it is reassuring that anti-resorptive therapy and mechanical loading can exert independent beneficial effects.This article is part of a Special Issue entitled Bisphosphonates.Research highlights: ► We assessed the combined effect of a bisphosphonate and loading on bone structure. ► Non-invasive tibia loading and a 1000-fold dose range of risedronate were used. ► Loading significantly increased both cortical and trabecular bone mass. ► Risedronate does not reduce the osteogenic effect of loading. (Source: Bone)

Adherence to osteoporosis medications amongst Singaporean patients

Osteoporosis International — Tue, 19 Apr 2011 06:50:12 +0100

Conclusion In contrast to studies conducted in the US and Europe that show poor adherence, our study suggests higher adherence rates to bisphosphonate therapy amongst Singaporean patients. Content Type Journal ArticlePages 1-8DOI 10.1007/s00198-011-1635-9Authors M. H. H. Cheen, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeM. C. Kong, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeR. F. Zhang, Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, 1 Hospital Drive, 169608 Singapore, SingaporeF. M. H. Tee, Department of Pharmacy, Singapore General Hospital, Singapore, SingaporeM. Chandran, Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hos...

Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes.

Journal of Proteomics — Mon, 11 Apr 2011 23:00:00 +0100

In conclusion, these findings unveil novel functions targeted by N-BPs in osteocytes and could be useful to design novel pharmaceutical compounds. PMID: 21504803 [PubMed - as supplied by publisher] (Source: Journal of Proteomics)

Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single‐center study

Transplant International — Mon, 04 Apr 2011 23:00:00 +0100

SummaryThe aim of this study was to investigate the effect of risedronate (RIS) on bone loss and bone turnover markers after liver transplantation (LT). Patients with osteopenia or osteoporosis within the first month after LT were randomized to receive RIS 35 mg/week plus calcium 1000 mg/day and vitamin D3 800 IU/day (n = 45) or calcium and vitamin D3 at same dosages (n = 44). Primary endpoint was change in bone mineral density (BMD) 6 and 12 months after LT. Secondary endpoints included changes in serum β‐CrossLaps (β‐CTX) and procollagen type 1 amino‐terminal peptide (P1NP) and fracture rate. Spine X‐rays were obtained at baseline and after 12 months. There was no significant difference in BMD changes between both treatment groups at any sites; either at 6 or ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Prevention of Bone Loss in Patients Taking Anti-Epileptic Drugs (AEDs)- Results of the Antiepileptic Drugs and Osteoporosis Prevention Trial (ADOPT).

Journal of Clinical Densitometry — Thu, 31 Mar 2011 23:00:00 +0100

Patients with epilepsy have a nearly twofold increase risk of vertebral or non-vertebral fractures as compared to the general population. It is known that long term use of AEDs is associated with an increased rate of bone loss. The primary objective of this trial was to evaluate whether the use of an oral bisphosphonate can help in preventing bone loss and osteoporosis in an epileptic population treated with phenytoin, phenobarbital, sodium valproate or carbamazepine. This investigator initiated study design is a phase IV, prospective, randomized, placebo controlled, double-blind study involving 80 male veterans with epilepsy who were being treated with the above AEDs for at least 2 years. Patients who were found to be osteoporotic according to WHO criteria (BMD T-score < -2.5 at spine or ...

Effects of Risedronate in Runx2 Overexpressing Mice, an Animal Model for Evaluation of Treatment Effects on Bone Quality and Fractures

Calcified Tissue International — Thu, 31 Mar 2011 17:40:38 +0100

In conclusion, young mice overexpressing Runx2 have high bone turnover-induced osteopenia and spontaneous fractures. Ris at 20 μg/kg weekly induced an increase in bone mass, changes in bone microarchitecture, and decreased vertebral fractures. Content Type Journal ArticlePages 1-12DOI 10.1007/s00223-011-9480-6Authors Valerie Geoffroy, INSERM U606, University Paris Diderot, Hôpital Lariboisière, Centre Viggo Petersen, 2 rue Ambroise Paré, 75010 Paris, FranceEleftherios P. Paschalis, Ludwig Boltzman Institute of Osteology at the Hanusch Hospital of WGKK, Heinrich Collin-Str. 30, 1140 Vienna, AustriaHelene Libouban, INSERM U922, LHEA Faculté de Médecine, 1 rue Haute de Reculée, 49045 Angers Cedex, FranceStephane Blouin, Ludwig Boltzman Institute of Osteology at the Hanusc...

Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36

Journal of Bone and Mineral Metabolism — Thu, 31 Mar 2011 17:37:51 +0100

Abstract Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis. In order to compare the effects of elcatonin and risedronate on such pain, 20 units of elcatonin was intramuscularly injected to 18 patients, and 5 mg of risedronate was orally administered daily to 20 others with similar backgrounds. Exercise-induced pain was analyzed by measuring the fall of skin impedance by electroalgometry (EAM), and subjective pain was recorded by a visual rating system (VRS) on a scale of 0 (no pain) to 100 (unbearable pain). In patients treated with elcatonin, the mean EAM-estimated pain was significantly reduced after 4, 5 and 6 months o...

Simultaneous bilateral subtrochanteric fractures following risedronate therapy

Journal of Orthopaedic Science — Tue, 29 Mar 2011 07:01:10 +0100

Content Type Journal ArticlePages 1-4DOI 10.1007/s00776-011-0058-yAuthors Mikko T. Ovaska, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, FinlandTatu J. Mäkinen, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, FinlandRami Madanat, Department of Surgery, Päijät-Häme Central Hospital, Keskussairaalankatu 7, 15850 Lahti, Finland Journal Journal of Orthopaedic ScienceOnline ISSN 1436-2023Print ISSN 0949-2658 (Source: Journal of Orthopaedic Science)

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Prostate Cancer and Prostatic Diseases — Tue, 22 Mar 2011 00:00:00 +0100

Authors: K Izumi, A Mizokami, K Sugimoto, K Narimoto, Y Kitagawa, E Koh & M Namiki (Source: Prostate Cancer and Prostatic Diseases)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Actonel with Calcium (Risedronate Sodium with Calcium Carbonate) - updated on RxList

RxList - New and Updated Drug Monographs — Fri, 18 Mar 2011 07:00:00 +0100

Actonel with Calcium (Risedronate Sodium with Calcium Carbonate) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

QJM — Thu, 17 Mar 2011 00:00:00 +0100

The primary goal of treatment for post-menopausal osteoporosis (PMO) is reduction in fracture risk. Therefore, clinicians must recommend therapies that are safe and have proven anti-fracture efficacy. Bisphosphonates have long been established as first-line therapy for osteoporosis and several of these drugs significantly reduce osteoporotic fracture risk. However, choosing among different bisphosphonates can represent a difficult clinical decision. This review outlines the pharmacology of various bisphosphonates, discusses how their pharmacological characteristics affect their efficacy, and summarizes clinical safety and efficacy data. Clinical trial data and the opinions of expert bodies suggest that alendronate, risedronate, ibandronate and zoledronic acid all provide fracture protectio...

Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.

Biochemical and Biophysical Research communications — Thu, 17 Mar 2011 00:00:00 +0100

Authors: Räikkönen J, Taskinen M, Dunford JE, Mönkkönen H, Auriola S, Mönkkönen J A class of drugs successfully used for treatment of metabolic bone diseases is the nitrogen-containing bisphosphonates (N-BPs), which act by inhibiting the vital enzyme, farnesyl pyrophosphate synthase (FPPS), of the mevalonate pathway. Inhibition of FPPS by N-BPs results in the intracellular accumulation of isopentenyl pyrophosphate (IPP) and consequently induces the biosynthesis of a cytotoxic ATP analog (ApppI). Previous cell-free data has reported that N-BPs inhibit FPPS by time-dependent manner as a result of the conformational change. This associated conformational change can be measured as an isomerization constant (K(isom)) and reflects the binding differences of the N-BPs to FPPS. In the pr...

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women

Osteoporosis International — Thu, 10 Mar 2011 17:13:41 +0100

Conclusions No significant differences were observed between the two groups. The incidence of unaffected side hip fracture was significantly lower in the risedronate group. Accordingly, risedronate may have a preventive effect on hip fracture in high-risk Japanese female osteoporosis patients for fracture with a history of unilateral hip fracture. Content Type Journal ArticlePages 1-9DOI 10.1007/s00198-011-1556-7Authors M. Osaki, Department of Orthopaedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501 JapanK. Tatsuki, Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka, 540-8645 JapanT. Hashikawa, Department of Orthopaedic Surgery, Nagasaki University Graduate School of Biomedical Sc...

Efficacy of risedronate with cholecalciferol on 25‐hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis

Clinical Endocrinology — Thu, 10 Mar 2011 00:00:00 +0100

Conclusion In patients with osteoporosis, a once‐weekly pill of risedronate and cholecalciferol provided equivalent anti‐resorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D level over a 16‐week treatment period without significant adverse events. (Source: Clinical Endocrinology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bisphosphonates for postmenopausal osteoporosis

Bone — Thu, 10 Mar 2011 00:00:00 +0100

This article is part of a Special Issue entitled Bisphosphonates.Research Highlights: ► Bisphosphonates reverse the key pathophysiological changes of postmenopausal osteoporosis. ► The bisphosphonates that have been licensed in many countries for postmenopausal osteoporosis include alendronate, ibandronate, risedronate and zoledronic acid. ► These bisphosphonates all reduce the level of bone turnover and increase the bone mineral density in postmenopausal osteoporosis. ► The bisphosphonates differ in their potency in their effects on bone turnover and bone density. ► The licensed bisphosphonates have all been shown to reduce the risk of vertebral fractures; some of them have also been shown to reduce the risk of non-vertebral and hip fractures. (Source: Bone)

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

Osteoporosis International — Wed, 02 Mar 2011 07:46:17 +0100

Conclusions Risedronate significantly reduced the risk of new vertebral fractures compared with placebo, regardless of PPI concomitant use. Content Type Journal ArticlePages 1-8DOI 10.1007/s00198-011-1574-5Authors C. Roux, Department of Rheumatology, AP-HP Cochin Hospital, Paris Descartes University, 27 rue Faubourg Saint Jacques, Paris, 75014 FranceJ. L. Goldstein, Department of Medicine, University of Illinois at Chicago, Chicago, IL USAX. Zhou, Procter & Gamble, Mason, OH USAA. Klemes, Procter & Gamble, Mason, OH USAR. Lindsay, Helen Hayes Hospital, West Havershaw, NY USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats

American Journal of Orthodontics and Dentofacial Orthopedics — Tue, 01 Mar 2011 00:00:00 +0100

Conclusions: Risedronate improved prednisolone-induced retardation of trabecular and cortical bone growth, but the bone turnover in these 2 sites was regulated differently in the growing rat mandibles. (Source: American Journal of Orthodontics and Dentofacial Orthopedics)

In vitro and in vivo antiplasmodial activity of risedronate and its interference with protein prenylation in P. falciparum.

Antimicrobial Agents and Chemotherapy — Mon, 28 Feb 2011 00:00:00 +0100

Authors: Jordão FM, Saito AY, Miguel DC, Peres VD, Kimura EA, Katzin AM The increasing resistance of malarial parasites to almost all available drugs calls for the identification of new compounds and the detection of novel targets. Herein, we establish the antimalarial activity of risedronate, one of the most potent bisphosphonates clinically used to treat bone resorption diseases, against blood stages of Plasmodium falciparum (IC50 20.3 ± 1.0 μM). We also suggest a mechanism of action for risedronate against the intraerythrocytic stage of P. falciparum, and show that protein prenylation seems to be directly modulated by this drug. Risedronate inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins, an effect not observed for the transfer of geranylgeranyl pyr...

Effect of Risedronate on Osteoblast Differentiation, Expression of Receptor Activator of NF‐κB Ligand and Apoptosis in Mesenchymal Stem Cells

Basic and Clinical Pharmacology and Toxicology — Fri, 18 Feb 2011 00:00:00 +0100

In this study, we investigated the effects of risedronate (RIS), a nitrogen‐containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC‐derived osteoblasts. The RANKL expression induced by 1,25‐(OH)2 vitamin D3 was not affected by RIS in human MSC‐derived osteoblasts. In addition, treatment with high concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS‐induced chromatin condensation was suppressed by a pan‐caspase inhibitor zVAD‐FMK and a cell permeable isoplenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiat...

MedWorm Sponsor Message: Find the best January Sales in the UK.

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 14 Feb 2011 05:00:00 +0100

Updated Date: Feb 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Good long-term adherence to osteoporosis prophylaxis decreases fracture risk but may be uncommon

NeLM - News — Wed, 09 Feb 2011 00:00:00 +0100

Source: Osteoporosis Int Area: News A large observational study from Sweden found that only a quarter of patients started on drugs for prophylaxis of osteoporosis were still taking them after 3 years, dropping to 14% after 4 years; however long-term use did reduce risk of fractures significantly. There is much evidence that persistence (long-term adherence) is poor with drugs for prophylaxis of osteoporosis, but reported values vary widely. The authors of this paper report experience from Sweden, using data from a historical cohort derived from Swedish prescribing registers. They extracted data on all patients aged 50 and over newly prescribed (no eligible prescription in previous five months) any one of alendronate, risedronate, strontium ranelate, and raloxifene between June ...

Dose-dependent Differential Effects of Risedronate on Gene Expression in Osteoblasts.

Biochemical Pharmacology — Fri, 04 Feb 2011 00:00:00 +0100

Authors: Wang J, Stern PH Bisphosphonates have multiple effects on bone. Their actions on osteoclasts lead to inhibition of bone resorption, at least partially through apoptosis. Effects on osteoblasts vary, with modifications in the molecule and concentration both resulting in qualitatively different responses. To understand the mechanism of the differential effects of high and low bisphosphonate concentrations on osteoblast activity, we compared the effects of 10(-8)M and 10(-4)M risedronate on gene expression in UMR-106 rat osteoblastic cells. Two targeted arrays, an 84-gene signaling array and an 84-gene osteogeneic array were used. Gene expression was measured at 1 and 24 hr. Although some genes were regulated similarly by low and high concentrations of the drug, there was also di...

[Bisphosphonate treatment of osteoporosis and other skeletal diseases.]

Tidsskrift for den Norske Laegeforening — Fri, 04 Feb 2011 00:00:00 +0100

Authors: Syversen U, Halse JI Background. Bisphosphonates are antiresorptive drugs widely used to treat osteoporosis. They are also used to treat hereditary skeletal diseases with systemic or local defects, and as a supplement in treatment of cancer. This paper provides an overview of pharmacokinetics, mode of action, and clinical effects. Material and methods. Literature was retrieved through a non-systematic search in Pubmed/Medline. Results. Bisphosphonates are derivates of pyrophosphate which bind to hydroxyapatite with high affinity. Aminobisphosphonates inhibit an enzyme in the mevalonate pathway, thereby inducing apoptosis and inhibiting osteoclast activity. A reduced incidence of vertebral and hip fractures has been shown for alendronate, risedronate and zoledronate, while iban...

Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA)

Osteoporosis International — Tue, 01 Feb 2011 09:21:42 +0100

Conclusions Persistence to treatment of osteoporosis in Sweden is poor and approximately 50% of all treatment-naïve patients discontinue therapy within 1 year. Average refill compliance, estimated only while the patients were persistent, was found to be close to perfect. A strong association was identified between treatment persistence and fracture incidence, which calls for action to improve the current situation. Content Type Journal ArticlePages 1-11DOI 10.1007/s00198-011-1549-6Authors E. Landfeldt, i3 Innovus, Stockholm, SwedenO. Ström, i3 Innovus, Stockholm, SwedenS. Robbins, Amgen (Europe) GmbH, Zug, SwitzerlandF. Borgström, i3 Innovus, Stockholm, Sweden Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteop...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

These Drugs Poison Your Bones

Al Sears, MD Natural Remedies — Tue, 25 Jan 2011 07:42:55 +0100

Dear Health Conscious Reader, Would you use a drug that gives you the problem it’s supposed to prevent? Well, that’s exactly what’s going on with the new osteoporosis drugs. Fosomax, Boniva, Reclast, Actonel … these medications are supposed to help stop you from getting bone fractures as you get older. But we now have evidence that they cause bone breaks. Researchers studied women taking these medications – called bisphosphonates – who experienced some sort of fracture. Over 65 percent had the same rare fracture in the same area of their thigh bones. And these were the women who had been on the drugs for the longest periods.1 Plus they’ve also found that if you’re on the drugs for a long time and you do get a bone break, you’ll heal very slowly. Sometimes it can take...

Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study

Journal of Bone and Mineral Metabolism — Tue, 11 Jan 2011 17:51:25 +0100

This study examined patients’ risk profiles and adherence to treatment in relation to the effect of risedronate and raloxifene on hip fracture incidence. Administrative billing data were used to follow two cohorts of women aged 65 and older after starting therapy with either risedronate (n = 86,735) or raloxifene (n = 37,726). The fracture risk profile was described using a 6-month history period before starting therapy. Effectiveness of each therapy was evaluated by comparing the incidence of hip fractures during the first 3 months with the subsequent 12 months among women adherent (medication possession ratio >80%) compared with those non-adherent to treatment. At the start of therapy, the raloxifene cohort was younger than the risedronate cohort (...

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

Osteoporosis International — Tue, 11 Jan 2011 07:29:10 +0100

Conclusions Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment. Content Type Journal ArticlePages 1-6DOI 10.1007/s00198-010-1525-6Authors S. A. Polyzos, Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34 Thessaloniki, GreeceA. D. Anastasilakis, Department of Endocrinology, 424 General Military Hospital, Thessaloniki, GreeceC. Bratengeier, Biomarker Design Forschungs GmbH, Vienna, AustriaW. Woloszczuk, ...

Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis

Rheumatology International — Fri, 07 Jan 2011 14:48:07 +0100

Abstract In addition to the well-described implications of estrogen deficiency in postmenopausal osteoporosis (PMO), free radicals are also effective on bone metabolism. The antioxidant vitamins C and E play an important role in the production of collagen, mesenchymal cell differentiation into osteoblasts, and bone mineralization. Therefore, the incidence of osteoporosis and the risk of fractures were decreased with vitamin C and E. It was proposed that free oxygen radicals are responsible for biological aging, atherosclerosis, carcinogenesis, and osteoclastic activity via their negative effects on the cell and DNA. In this study, we aimed to investigate and compare the levels of free radicals and serum antioxidant activity in patients with PMO and healthy subjects before ...

Recalls and Safety Alerts: Update on Femur Fracture Risk with Bisphosphonates

Food and Drug Adminstration (FDA): Patient Safety News — Sat, 01 Jan 2011 05:00:00 +0100

The FDA has issued updated information on atypical fractures of the femur associated with the use of bisphosphonates to treat osteoporosis. These drugs include Fosamax (alendronate sodium), Actonel (risedronate sodium), Boniva (ibandronate sodium), ... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Pain Physician — Sat, 01 Jan 2011 00:00:00 +0100

Authors: Reginster JY Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad for consideration in osteoporosis is morbidity, mortality and cost. Vertebral fracture is an important source of morbidity in terms of pain and spinal deformity. On the other hand, hip fracture is associated with the worst outcomes and is widely regarded as a life-threatening event in the elderly; it is the source of the bulk of the cost of the disease in contemporary healthcare. The prevention of osteoporosis-associated fracture should include fall ...

Spontaneous Supracondylar Femoral Fracture in an HIV Patient in Lotus Position

Journal of Clinical Densitometry — Sat, 01 Jan 2011 00:00:00 +0100

Abstract: Bone disorders have been described in patients chronically infected with human immunodeficiency virus (HIV). A case of spontaneous supracondylar femoral fracture that occurred in a 58-year-old monk during meditation is reported. His AIDS disease was controlled with combination antiretroviral therapy. Vitamin D and calcium had been added 3yr before since osteoporosis was detected by dual-energy X-ray absorptiometry (DXA). At the time of the fracture, the patient was on treatment with 35mg every week of sodium risedronate, 1000mg of calcium, and 400IU of Vitamin D every day. Clinical use of DXA for HIV patients should be considered as a routine measure to help reducing risk for fractures. (Source: Journal of Clinical Densitometry)

Transformation of hemipenta hydrate to mono hydrate of risedronate monosodium by seed crystallization in solution

AIChE Journal — Thu, 30 Dec 2010 07:47:00 +0100

AbstractThe transformation from a hemipenta to a mono hydrate of risedronate monosodium(RS) was studied by seed crystallization in solution. By using the in‐line measurement based on ultrasonic measuring technique and the off‐line measurements such as optical microscopic and crystallography, transformation of hydrate forms and crystallization of monohydrate were observed. The effect of concentration of solution and solid fraction of suspension on the ultrasonic velocity was found. The hydrate composition, concentration of solution and supersaturation during the transformation were estimated with elapsed time. The effect of mono hydrate seed, agitation rate and temperature on the induction time, transformation and crystallization was also investigated. Eventually transformation from hem...

Transformation of hemipentahydrate to monohydrate of risedronate monosodium by seed crystallization in solution

AIChE Journal — Wed, 29 Dec 2010 00:00:00 +0100

AbstractThe transformation from a hemipentahydrate to a monohydrate of risedronate monosodium was studied by seed crystallization in solution. By using the in‐line measurement based on ultrasonic measuring technique and the off‐line measurements such as optical microscopic and crystallography, transformation of hydrate forms and crystallization of monohydrate were observed. The effect of concentration of solution and solid fraction of suspension on the ultrasonic velocity was found. The hydrate composition, concentration of solution, and supersaturation during the transformation were estimated with elapsed time. The effect of monohydrate seed, agitation rate and temperature on the induction time, transformation, and crystallization was also investigated. Eventually, transformation from...

One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study

Bone — Tue, 28 Dec 2010 22:19:53 +0100

Introduction: Bone loss is a well known complication of aromatase inhibitor therapy in breast cancer patients. The bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) is a randomized, placebo-controlled, double-blind trial to study the effect of anastrozole (1mg/day) on bone mineral density (BMD) and to evaluate the impact of oral risedronate on bone loss in healthy postmenopausal women at a high risk of breast cancer. Materials and Methods: Lumbar spine (LS) and total hip (TH) BMD at baseline and 1year were available for 657 women at the time of analysis. Of these, 384 with normal BMD (stratum-I) received only monitoring with DXA scans, 194 osteopenic women (stratum-II) were randomised to receive either risedronate 35mg/week or placebo and 79 osteoporotic women en...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates

The Pharmacogenomics Journal — Tue, 14 Dec 2010 00:00:00 +0100

Authors: J M Olmos, M T Zarrabeitia, J L Hernández, C Sañudo, J González-Macías & J A Riancho (Source: The Pharmacogenomics Journal)

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 10 Dec 2010 05:00:00 +0100

Updated Date: Dec 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Proposed new approach for treating Paget’s disease of bone

Irish Journal of Medical Science — Mon, 06 Dec 2010 15:08:55 +0100

Conclusions Newly diagnosed patients with PDB should be treated for 6 months with oral N-BPs prior to administration of intravenous ZA. Repeat ZA infusions are necessary only if the serum total ALP levels rise above normal, or if symptoms or complications attributable to PDB persist. Content Type Journal ArticleDOI 10.1007/s11845-010-0652-6Authors W. Mahmood, St. Michaels Hospital, Lower George’s Street, Dún Laoghaire, Co. Dublin IrelandM. J. McKenna, St. Michaels Hospital, Lower George’s Street, Dún Laoghaire, Co. Dublin Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)

ATELVIA (Risedronate Sodium) Tablet, Delayed Release [Warner Chilcott (US), LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 01 Dec 2010 05:00:00 +0100

Updated Date: Dec 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis

Journal of Bone and Mineral Metabolism — Tue, 30 Nov 2010 07:01:01 +0100

In conclusion, Japanese osteoporotic women treated by either alendronate or risedronate showed significant improvements of geometry in proximal femur within 1 year. Content Type Journal ArticleDOI 10.1007/s00774-010-0242-8Authors Junichi Takada, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, JapanGenichiro Katahira, Sapporo Kiyota Orthopaedic Hospital, Sapporo, JapanKousuke Iba, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, JapanTakashi Yoshizaki, Kitago Orthopedic Clinic, Kitago, 3jyo-8, 5-33, Shiroishi-ku, Sapporo, 003-0833 JapanToshihiko Yamashita, Department of Orthopedic Surgery, Sapporo Medical University, Sapporo, Japan Journal Journal of Bone and Mineral MetabolismOnline ISSN 1435-5604Print ISSN 0914-8779 (Source:...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Computational Insights into Binding of Bisphosphates to Farnesyl Pyrophosphate Synthase.

Current Medicinal Chemistry — Mon, 29 Nov 2010 00:00:00 +0100

Authors: Ohno K, Mori K, Orita M, Takeuchi M Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Paget's disease. Non-nitrogen containing BPs (non-N-BPs), namely etidronate, clodronate, tiludronate, as well as nitrogencontaining BPs (N-BPs), namely pamidronate, alendronate, ibandronate, risedronate, zoledronate and minodronate have been launched on the market to date. N-BPs act by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS), and several crystal structures of complexes between FPPS and N-BPs have been revealed. Understanding the physical basis of the binding between protein and small molecules is an important goal in both medicinal chemistry and structural biology. In this review, we analyze in detail the energetic basis of molecu...

Osteoporosis in Men: What has Changed?

Current Osteoporosis Reports — Fri, 26 Nov 2010 18:09:04 +0100

Abstract Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture. Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram. Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors. Alendronate, risedronate, zoledronic acid, and teriparatide are US Food and Drug Administration (FDA)—approved therapy for men. Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density. The new antiresorptive drug, denosumab, although FDA-approved onl...

Bisphosphonates in phenytoin-induced bone disorder

Bone — Mon, 22 Nov 2010 00:00:00 +0100

Abstract: Chronic administration of phenytoin (PHT) has been associated with bone loss. Bisphosphonates [alendronate (ALD), ibandronate (IBD) and risedronate (RSD)] are potential candidates to prevent PHT-induced bone disorders, and the present study evaluated their effect on the antiepileptic efficacy of PHT. The PHT-induced depletion in folic acid (FA), vitamin B6 and vitamin B12 results in hyperhomocysteinemia. The elevated circulating homocysteine (hcy) could be a risk indicator for micronutrient-deficiency-related osteoporosis via generation of free radicals. Thus, an attempt was also made to unravel the PHT's and bisphosphonates' effect on hcy. Male mice received PHT (35mg/kg, p.o.) for 90days to induce bone loss. ALD, RSD and IBD were administered orally at doses 0.65mg/kg, 0.33mg/k...

Atelvia (Risedronate Sodium Delayed-Release Tablets) - updated on RxList

RxList - New and Updated Drug Monographs — Thu, 04 Nov 2010 07:00:00 +0100

Atelvia (Risedronate Sodium Delayed-Release Tablets) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

Breast Cancer Research and Treatment — Tue, 02 Nov 2010 17:23:08 +0100

The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0....

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Erratum to: Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate

Calcified Tissue International — Sat, 23 Oct 2010 15:45:58 +0100

Content Type Journal ArticleDOI 10.1007/s00223-010-9430-8Authors Stuart H. Ralston, Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, EH4 2XU UKTzuyung D. Kou, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USABettina Wick-Urban, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USAMichael Steinbuch, Procter & Gamble Pharmaceuticals, Inc., Mason, OH USATahir Masud, Nottingham University Hospitals NHS Trust, Nottingham, UK Journal Calcified Tissue InternationalOnline ISSN 1432-0827Print ISSN 0171-967X (Source: Calcified Tissue International)

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

Bone — Thu, 21 Oct 2010 00:00:00 +0100

In conclusion, our results suggest that low concentrations of N-BPs inhibit angiogenesis in a FPPS-independent manner, whereas higher drug concentrations were required to inhibit FPPS activity in vivo. (Source: Bone)

FDA: Osteoporosis Drugs May Raise Thigh Fracture Risk

WebMD Health — Wed, 13 Oct 2010 22:37:28 +0100

The bisphosphonate class of osteoporosis drugs -- including Actonel, Atelvia, Boniva, Fosamax, Reclast, and generics -- may riase the risk of thigh-bone fracture, the FDA warns. (Source: WebMD Health)

Bisphosphonates (Osteoporosis Drugs): Label Change - Atypical Fractures Update

Drugs.com - FDA MedWatch Alerts — Wed, 13 Oct 2010 04:00:00 +0100

Audience: Patient, Family Practice, Geriatric including Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast ISSUE: FDA is updating the public regarding information previously communicated describing the risk of... (Source: Drugs.com - FDA MedWatch Alerts)

Warner Chilcott Announces FDA Approval of Next Generation Actonel

HSMN NewsFeed — Mon, 11 Oct 2010 21:02:02 +0100

ARDEE, Ireland, Oct. 11 (HSMN NewsFeed) -- Warner Chilcott plc (Nasdaq:WCRX ) today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postme... Biopharmaceuticals, FDAWarner Chilcott, ACTONEL, risedronate, osteoporosis (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel

Drugs.com - New Drug Approvals — Mon, 11 Oct 2010 16:10:12 +0100

ARDEE, Ireland, October 11, 2010 /PRNewswire-FirstCall/ -- Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation Actonel (risedronate sodium) product for the treatment... (Source: Drugs.com - New Drug Approvals)

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Osteoporosis International — Sat, 09 Oct 2010 06:01:26 +0100

Conclusion Improving persistence with osteoporosis treatment impacts positively on cost-effectiveness with a larger number of fractures avoided in the population targeted for treatment. Denosumab is a cost-effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture and low expected adherence to oral treatments. Content Type Journal ArticleDOI 10.1007/s00198-010-1424-xAuthors B. Jönsson, Stockholm School of Economics, Box 6501, SE 11383 Stockholm, SwedenO. Ström, i3 Innovus, Stockholm, SwedenJ. A. Eisman, UNSW, Garvan Institute of Medical Research, St Vincent’s Hospital, Sydney, AustraliaA. Papaioannou, McMaster University, Hamilton, ON CanadaE. S. Siris, Columbia University, New York, NY USAA. Tosteson, Dartmouth Me...

Osteoporotic fracture prevention guidance

Nursing Times Breaking News — Sun, 26 Sep 2010 07:00:00 +0100

Postmenopausal women at increased risk of osteoporotic fractures should be treated with denosumab (Prolia), if treatment with the oral bisphosphonates alendronate, risedronate or etidronate is unsuitable, according to draft guidance from NICE. (Source: Nursing Times Breaking News)

Switching osteoporosis drugs 'increases GI risk'

Pulse — Mon, 20 Sep 2010 15:21:00 +0100

Patients with osteoporosis who are switched from risedronate to alendronate have a much higher risk of developing an adverse gastrointestinal event, a UK study shows. (Source: Pulse)

Final Draft Guidance Recommends Osteoporosis Treatment As A New Option For Women At Increased Risk Of Fractures

Health News from Medical News Today — Wed, 15 Sep 2010 14:00:00 +0100

Postmenopausal women who are at increased risk[1] of osteoporotic fractures should be treated with denosumab if treatment with the currently available oral bisphosphonates alendronate, and either risedronate or etidronate is unsuitable, according to draft guidance published today (Wednesday 15 September) by NICE. Denosumab (Prolia, Amgen) is licensed to treat postmenopausal women at increased risk of osteoporotic fractures. It is given by injection twice a year and works by reducing bone breakdown and increasing bone mass and strength... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

NICE issues Final Appraisal Determination (FAD) on denosumab for osteoporotic fractures

NeLM - News — Tue, 14 Sep 2010 23:00:00 +0100

Source: NICE Area: News After considering the feedback from consultation, the Appraisal Consultation Committee has published a Final Appraisal Determination (FAD) on denosumab for the prevention of osteoporotic fractures in postmenopausal women and submitted it to the Institute. The FAD states the following: Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures: . who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and . who have a combination of T-score, age and number of independent clinical risk ...

The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis

Seminars in Arthritis and Rheumatism — Thu, 09 Sep 2010 00:00:00 +0100

Conclusion: Of the available bisphosphonates for osteoporosis, zoledronic acid has the highest probability of offering the best overall fracture protection. (Source: Seminars in Arthritis and Rheumatism)

Bone drugs and cancer rates

NHS News Feed — Mon, 06 Sep 2010 11:11:00 +0100

Conclusion This was a large cohort study that looked at whether using oral bisphosphonates for osteoporosis increased the risk of oesophageal, stomach or colorectal cancer. The study was well conducted and accounted for other factors that could affect the risk of these types of cancer, most importantly smoking and alcohol consumption. Although the study found that people taking many prescriptions of these drugs over a long time had an increased risk compared to patients who had never taken these drugs, there are limitations to this study, some of which were raised by the researchers. Points for consideration include: The researchers had prescription data but no information on how the patients took the drugs. For example, this type of drug will contain safety information designed to mini...

Bone-building drugs double the risk of esophageal cancer, but the risk is still small

OrlandoSentinel: Medical Research — Fri, 03 Sep 2010 10:17:00 +0100

The family of bone-building drugs that includes Fosamax, Actonel and Boniva can double the risk of developing throat cancer, researchers reported Thursday in the latest development in what has become a confusing discussion. Other studies have reported... (Source: OrlandoSentinel: Medical Research)

Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women

Calcified Tissue International — Thu, 02 Sep 2010 06:16:50 +0100

In conclusion, risedronate 5 mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone. Content Type Journal ArticleDOI 10.1007/s00223-010-9411-yAuthors S. Qiu, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USAR. J. Phipps, Husson University School of Pharmacy, 1 College Circle, Bangor, ME USAF. H. Ebetino, Warner Chilcott, Mason Business Center, Mason, OH USAS. Palnitkar, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USAD. Sudhaker Rao, Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USA Journal Calcifi...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Osteoporosis Drugs May Be Linked to Cancer Risk

WebMD Health — Thu, 02 Sep 2010 05:00:00 +0100

The long-term use of oral bisphosphonate osteoporosis drugs such as Actonel, Boniva, and Fosamax may be associated with a doubling in esophageal cancer risk, but the risk to individual users remains small, researchers say. (Source: WebMD Health)

[Jaw osteonecrosis induced by oral biphosphonates: 12 cases.]

Revue de Stomatologie et de Chirurgie Maxillo-Faciale — Sun, 29 Aug 2010 23:00:00 +0100

We report 12 cases of JONOBP observed from January 2007 to January 2009. MATERIAL AND METHODS: A pluridisciplinary committee including odontologists, stomatologists, and maxillofacial surgeons from two Paris hospitals was asked to manage patients treated by BP. Twelve patients presenting with JONOBP were included from January 2007 to January 2009. For each of these patients, age, sex, associated co-morbidities, any triggering factor, previous or current combination treatments, the type of BP used, its initial indication, dosage, delay before onset of JONOBP, and delay between first clinical signs and diagnosis were studied. JONOBP localization, stage (American Association of Oral and Maxillofacial Surgeons [AAOMS] classification), clinical and radiological signs, anatomopathological and ba...

Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate

Calcified Tissue International — Sat, 28 Aug 2010 17:02:02 +0100

Abstract Upper gastrointestinal (GI) side effects are a known complication of therapy with oral aminobisphosphonates, but it is currently unclear if bisphosphonate type or formulation influences the risk of developing side effects. Here, we performed a retrospective cohort study to determine if patients who switched from weekly risedronate to weekly alendronate had an increased risk of upper GI side events. The study utilized The Health Improvement Network (THIN) database, which contained anonymous medical records from 390 general practices in the United Kingdom. The study was performed following the introduction of generic alendronate preparations, by which point 94% of alendronate prescriptions were for the generic formulation. We identified 3,446 patients who had been s...

Community based intervention to optimize osteoporosis management: randomized controlled trial

BMC Geriatrics — Thu, 26 Aug 2010 23:00:00 +0100

Conclusions: A multi-faceted community-based intervention improved management of osteoporosis in high risk patients compared with usual care.Trial Registration: This trial has been registered with clinicaltrials.gov (ID: NCT00465387) (Source: BMC Geriatrics)

The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation

Arthritis Research and Therapy — Tue, 24 Aug 2010 23:00:00 +0100

IntroductionThe purpose of this study was to evaluate the effects of risedronate (Ris) in the modulation of bone formation in rats with glucocorticoid (GC) - induced osteoporosis by histomorphometric, immunohistochemical and gene expression analyses. Methods: We analyzed structure, turnover and microarchitecture, cyclooxygenase 2 (COX-2) levels and osteocyte apoptosis in 40 female rats divided as follows: 1) vehicle of methylprednisolone (vGC) + vehicle of risedronate (vRis); 2) Ris 5[microg]/Kg + vGC; 3) methylprednisolone (GC) 7mg/Kg + vRis; 4) GC 7mg/Kg +Ris 5[microg]/Kg. In addition, we evaluated cell proliferation and expression of COX-2 and bone alkaline phosphatase (b-ALP) genes in bone marrow cells and MLO-y4 osteocytes treated with Ris alone or in co-treatment with the selective C...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Synthesis and biological evaluation of a series of aromatic bisphosphonates.

Bioorganic and Medicinal Chemistry — Wed, 18 Aug 2010 23:00:00 +0100

Authors: Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF Geminal bisphosphonates display varied biological activity depending on the nature of the substituents on the central carbon atom. For example, the nitrogenous bisphosphonates zoledronate and risedronate inhibit the enzyme farnesyl diphosphate synthase while digeranyl bisphosphonate has been shown to inhibit the enzyme geranylgeranyl diphosphate synthase. We now have synthesized isoprenoid bisphosphonates where an aromatic ring has been used to replace one of the isoprenoid olefins in an isoprenoid bisphosphonate and investigated the ability of these new compounds to impair protein geranylgeranylation within cells. Several of these new compounds are potent inhibitors of the enzyme geranylgeranyl diphosphate synthase. PMI...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 Aug 2010 05:00:00 +0100

Updated Date: Aug 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate

Bone — Thu, 05 Aug 2010 23:00:00 +0100

This article is part of a Special Issue entitled Bisphosphonates. (Source: Bone)

Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.

Journal of Orthopaedic Surgery — Sat, 31 Jul 2010 23:00:00 +0100

CONCLUSION. Continuous local injection of risedronate into the lengthened segment can prevent osteopenia during distraction osteogenesis but fails to enhance mechanical strength of newly distracted segments. PMID: 20808018 [PubMed - in process] (Source: Journal of Orthopaedic Surgery)

Effects of risedronate on bone marrow adipocytes in postmenopausal women

Osteoporosis International — Tue, 27 Jul 2010 09:06:07 +0100

Conclusions Risedronate reduces bone marrow fat in postmenopausal women. These findings are the first demonstration of an effect of bisphosphonates on marrow fat in humans in vivo. By regulating the amount of fat within the bone marrow, this effect may contribute to the beneficial effect of bisphosphonates on bone mass. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-010-1353-8Authors G. Duque, The University of Sydney Aging Bone Research Program, Sydney Medical School—Nepean Campus Penrith NSW AustraliaW. Li, The University of Sydney Aging Bone Research Program, Sydney Medical School—Nepean Campus Penrith NSW AustraliaM. Adams, The University of Sydney Aging Bone Research Program, Sydney Medical School—Nepean Campus Penrith NSW Austral...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Strategies for Strengthening Patent Protection of Pharmaceutical Inventions in Light of Federal Court Decisions.

Current Topics in Medicinal Chemistry — Wed, 07 Jul 2010 23:00:00 +0100

Authors: Pillai X, Kinney WA In this article, a brief history of patent law is presented, along with recent changes in its interpretation that are relevant in securing patents in the current landscape. Specific patent examples are presented to illustrate key issues. For example, the case of KSR International Co. v. Teleflex, Inc. is an important recent decision by the United States Supreme Court, which developed a more flexible definition of the teaching-suggestion-motivation (TSM) test in determining obviousness, which negates patentability. Although KSR case involved a mechanical invention, the ruling in this case has had implications in other areas of patent law, particularly as it applied to pharmaceutical and chemical inventions. It has had a significant impact on the outcome of p...

Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.

European Journal of Pharmaceutical Sciences — Mon, 05 Jul 2010 23:00:00 +0100

Authors: Dissette V, Bozzi P, Bignozzi CA, Dalpiaz A, Ferraro L, Beggiato S, Leo E, Vighi E, Pasti L Adducts based on a bisphosphonate drug (sodium risedronate) and titanium dioxide (TiO(2)) particles have been developed and characterized in order to improve the bioavailability of orally administrated bisphosphonates. Nanocrystalline and colloidal TiO(2), both characterized by powder X-ray diffraction, were used to obtain the adducts 1 and 2, respectively. Adducts 1 and 2 appeared constituted by nanoparticles of about 50 and 90nm grouped in clusters of about 0.2 and 2.5mum, respectively. Higher amounts of drugs were adsorbed on adduct 2 (7.2+/-0.3%) with respect to adduct 1 (4.0+/-0.3%). In vitro studies demonstrate that the adducts were able to release the drug in the pH range 6-9, wh...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 01 Jul 2010 05:00:00 +0100

Updated Date: Jul 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

How do bisphosphonates inhibit bone metastasis in vivo?

Neoplasia — Wed, 30 Jun 2010 23:00:00 +0100

Authors: Fournier PG, Stresing V, Ebetino FH, ClÃ©zardin P Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of bone resorption remains unclear. To address this question, we used here a structural analog of the bisphosphonate risedronate, NE-58051, which has a bone mineral affinity similar to that of risedronate, but a 3000-fold lower bone antiresorptive activity. In vitro, risedronate and NE...

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

Breast Cancer Research — Thu, 17 Jun 2010 23:00:00 +0100

The use of adjuvant aromatase inhibitors is associated with an increase risk of osteoporosis and fractures. The oral bisphosphonate, risedronate, dosed as FDA approved for the treatment or prevention of postmenopausal osteoporosis, appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early stage breast cancer (Source: Breast Cancer Research)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

The pros and cons of Prolia, Amgen's new osteoporosis drug

L.A. Times - Health — Sat, 12 Jun 2010 02:04:24 +0100

Bone-weakened patients who cannot take Fosamax and its cousins may find it a good alternative. The U.S. Food and Drug Administration approved a new drug for osteoporosis this month. Amgen's Prolia (denosumab) prevents fractures in postmenopausal women at a rate similar to the most popular drugs on the market — bisphosphonates such as Fosamax, Actonel, Boniva and Reclast. (Source: L.A. Times - Health)

Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study

Journal of Bone and Mineral Metabolism — Wed, 09 Jun 2010 09:17:23 +0100

Abstract The purpose of this practice-based observational study was to clarify the acute effect of risedronate on proximal femur bone mineral density (BMD) and structural geometry in patients with an increased risk of fractures. One hundred sixty-four patients (7 men and 157 postmenopausal women; mean age, 69.2 years) with osteoporosis or osteopenia and clinical risk factors of fractures were analyzed. All these patients were treated with risedronate for 1 year. Urinary levels of cross-linked N-terminal telopeptide of type I collagen (NTX) were measured at baseline and 4 months after the start of treatment. BMD of the lumbar spine and proximal femur and structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry w...

Management of Anastrozole-Induced Bone Loss in Breast Cancer Patients With Oral Risedronate: Results From the ARBI Prospective Clinical Trial

Medscape Today Headlines — Thu, 03 Jun 2010 16:04:04 +0100

Preventive treatment for those at risk for bone loss may minimize adverse effects of anastrozole. Breast Cancer Research (Source: Medscape Today Headlines)

Long-Term Osteoporosis Drug Use May Harm Bone

OrlandoSentinel: Medical Research — Tue, 01 Jun 2010 23:00:00 +0100

Medications called bisphosphonates are standard tools for the treatment of osteoporosis. They include Fosamax, Boniva, Actonel and Reclast. But new data released raise some concern about whether the drugs are safe for long-term use. Although the... (Source: OrlandoSentinel: Medical Research)

Osteoporosis Drug Use May Harm Bone Over Long-Term

OrlandoSentinel: Medical Research — Tue, 01 Jun 2010 23:00:00 +0100

MedWorm Sponsor Message: Find the best January Sales in the UK.

Management of osteoporosis in a pre-menopausal woman

Best Practice and Research. Clinical Rheumatology — Mon, 31 May 2010 14:23:05 +0100

There is no agreed definition of osteoporosis in pre-menopausal women. The International Society for Clinical Densitometry recommends using Z-score, and women with Z-scores of −2.0 or lower should be defined as having a bone density that is ‘below the expected range for age’. The diagnosis is more readily made in the presence of a low-trauma fracture. The relationship between low bone mineral density (BMD) in young pre-menopausal women and its associated fracture risk is not the same as in older women with a low BMD. Between 50% and 90% of pre-menopausal women will have an underlying secondary cause, the most common being eating disorders, anorexia nervosa and use of glucocorticoids. Management should focus on identifying the underlying cause and treating it where possible. The use o...

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

BJU International — Fri, 30 Apr 2010 23:00:00 +0100

(Source: BJU International)

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

BJU International — Thu, 29 Apr 2010 23:00:00 +0100

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To determine whether increased bone loss and bone turnover during the first 6 months of therapy for prostate cancer with luteinizing hormone-releasing hormone (LHRH)-agonist therapy could be prevented by bisphosphonate therapy with risedronate 35 mg/week, as prostate cancer is commonly treated with LHRH agonists and this often leads to rapid bone loss within the first 6 months of therapy. A 6-month randomized, double-blind, placebo-controlled trial was conducted, including 40 men aged [ge]55 years receiving LHRH-agonist treatment for 6 months for locally advanced prostate cancer. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip was measured every 6 months. In addition, bone turnover markers including N-telopept...

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Warner Chilcott Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 29 Apr 2010 05:00:00 +0100

Updated Date: Apr 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget’s disease of bone

Osteoporosis International — Wed, 21 Apr 2010 08:55:56 +0100

We describe hereby the case of a patient with Paget’s disease of bone accompanied by nonalcoholic fatty liver disease (NAFLD) who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. NAFLD had been diagnosed 1 year before presentation, based on liver ultrasonography (US). One day after infusion, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 8.1, 6.7, and 6.7 times, respectively, compared with pretreatment values. Serum bilirubin remained normal. US revealed hepatic mild homogenous brightness without focal lesion of the liver or biliary ducts. Subsequent biochemical and serologic investigation did not reveal a specific liver or systematic disease. The patient remained asymptomat...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 16 Apr 2010 05:00:00 +0100

Updated Date: Apr 16, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Breast Cancer Research — Thu, 15 Apr 2010 23:00:00 +0100

IntroductionThe aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). Methods: Pre-treatment BMD of 213 patients with hormone receptor-positive BC was evaluated at lumbar spine (LS) and hip (HP). Patients were categorized according to their baseline BMD T-score at low, moderate and high risk of osteoporosis. Low risk patients received anastrozole only (A), moderate risk were randomized to anastrozole +/- risedronate (A+/-R) administration and high risk patients received anastrozole + risedronate (A+R). Anastrozole was given at a dosage of 1mg/day while oral risedronate was given at 35mg/week. BMD was th...

Warner Chilcott Announces Amendment to Actonel Collaboration Agreement with sanofi-aventis

Drugs.com - Pharma News — Mon, 05 Apr 2010 12:40:57 +0100

ARDEE, Ireland, April 5 /PRNewswire-FirstCall/ -- Warner Chilcott plc (NASDAQ:WCRX) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today an amendment to the Actonel® global collaboration agreement with respect to the... (Source: Drugs.com - Pharma News)

Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies

Journal of the American Geriatrics Society — Mon, 22 Mar 2010 00:00:00 +0100

To quantify the effect of age on the incidence of osteoporosis-related fractures and of risedronate treatment on fracture risk in different age groups in women with postmenopausal osteoporosis. Data from four randomized, double-blind, placebo-controlled, Phase III studies were pooled and analyzed. The analysis population (N=3,229) consisted of postmenopausal women with osteoporosis as determined on the basis of prevalent vertebral fractures, low bone mineral density (BMD), or both. Patients had received risedronate 5 mg daily or placebo for 1 to 3 years. The endpoints of interest were the incidence of osteoporosis-related fractures, clinical fractures, nonvertebral fractures, and morphometric vertebral fractures. The effect of age on fracture risk and treatment benefit was examined using C...

Long-term use of popular osteoporosis drugs may harm bone

OrlandoSentinel: Medical Research — Sat, 13 Mar 2010 00:00:00 +0100

Medications called bisphosphonates are standard tools for the treatment of osteoporosis. They include Fosamax, Boniva, Actonel and Reclast. But new data released this month raise some concern about whether the drugs are safe for long-term use. Although... (Source: OrlandoSentinel: Medical Research)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.

Thu, 11 Mar 2010 17:14:03 +0100

Authors: Zhang L A simple method has been developed for the analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography (RPLC) with evaporative light-scattering detection (ELSD). After optimization of the chromatographic conditions, satisfactory separation of the compounds was achieved on an Intersil C(8) column with an isocratic mobile phase: 8:4:88 (v/v) acetonitrile-methanol-12 mM ammonium acetate buffer containing 35 mM n-amylamine (pH 7.0). The mobile-phase flow rate was 1.0 mL min(-1). The calibration plot was linear in the range of 352 to 1760 mug mL(-1) for risedronate. The precision and reproducibility were 0.3 and 0.5%, respectively. The average recovery of risedronate was 100.4% and the RSD was 0.6%. The method was validat...

High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment

Journal of Bone and Mineral Metabolism — Thu, 11 Mar 2010 02:41:33 +0100

In conclusion, measurement of undercarboxylated osteocalcin may be useful for assessing fracture risk in patients receiving amino-BP treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-010-0167-2Authors Masataka Shiraki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanYasushi Yamazaki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanYumiko Shiraki, Research Institute and Practice for Involutional Diseases 1610-1 Meisei, Misato Azumino Nagano 299-8101 JapanTakayuki Hosoi, National Center for Geriatrics and Gerontology Department of Clinical Research and Development Aichi JapanNaoko Tsugawa, Kobe Pharmaceutical University Department ...

Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis?

Current Osteoporosis Reports — Thu, 11 Mar 2010 02:24:30 +0100

Abstract Osteoporosis and fractures are under-recognized and undertreated, both in men and women worldwide. Male osteoporosis is not the epidemic problem that female osteoporosis is; however, the National Osteoporosis Foundation estimates that over 14 million American men have osteoporosis or low bone mass, and approximately 25% to 30% of all hip fractures occur in male individuals who incur greater morbidity and mortality than their female counterparts. Until recently, alendronate, risedronate, and teriparatide were the only pharmacologic agents approved by the US Food and Drug Administration for treating male osteoporosis. In December 2008, zoledronic acid was approved for “treatment to increase bone mass in men with osteoporosis.” In 2009, zoledronic acid was also a...

An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral.

ChemMedChem — Fri, 05 Mar 2010 00:00:00 +0100

Authors: Jahnke W, Henry C Targeted delivery of drugs to their site of action is a promising strategy to decrease adverse effects and enhance efficacy, but successful applications of this strategy have been scarce. Human bone is a tissue with unique properties due to its high hydroxyapatite mineral content. However, with the exception of bisphosphonates, bone mineral has not been targeted in a successful clinical application of drugs that act on bone, such as anti-resorptive or bone anabolic agents. Herein we present an NMR-based in vitro assay to measure binding affinities of small molecules to hydroxyapatite (HAP) or bone powder. Binding was shown to be specific and competitive, and the assay can be carried out in a direct binding format or in competition mode. A selection of clinica...

Effects of risedronate on osteoarthritis of the knee.

Yonsei Medical Journal — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Iwamoto J, Takeda T, Sato Y, Matsumoto H The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cart...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget’s disease of bone

Journal of Bone and Mineral Metabolism — Wed, 24 Feb 2010 06:49:48 +0100

In conclusion, treatment with high-dose risedronate for 8 weeks resulted in clinically significant and sustained improvement of biochemical markers of bone turnover for 48 weeks in patients with PDB, and this improvement was associated with a decrease of RI uptake by Paget’s bone lesions and with reduced pain. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-009-0152-9Authors Kousei Yoh, Sasayama Hospital, Hyogo Medical College Department of Orthopedic Surgery 75 Yamauchi-cho Sasayama 669-2337 JapanShinjiro Takata, University of Tokushima Graduate School Department of Orthopedics, Institute of Health Biosciences Tokushima JapanNoriko Yoshimura, University of Tokyo Department of Joint Disease Research, 22nd Medical and Research Center Tokyo JapanJ...

Long-Term Use of Bisphosphosphonates in Osteoporosis.

The Journal of Clinical Endocrinology and Metabolism — Fri, 19 Feb 2010 00:00:00 +0100

Conclusions: Bisphosphonates are popular and effective for treatment of osteoporosis. Because they accumulate in bone and provide some residual antifracture reduction when treatment is stopped, we recommend a drug holiday after 5-10 yr of bisphosphonate treatment. The duration of treatment and length of the holiday are based on fracture risk and pharmacokinetics of the bisphosphonate used. Patients at mild risk might stop treatment after 5 yr and remain off as long as bone mineral density is stable and no fractures occur. Higher risk patients should be treated for 10 yr, have a holiday of no more than a year or two, and perhaps be on a nonbisphosphonate treatment during that time. PMID: 20173017 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Meta...

Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial [Breast Cancer]

Journal of Clinical Oncology — Thu, 18 Feb 2010 23:00:37 +0100

Conclusion In postmenopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable effects in BMD during 24 months. (Source: Journal of Clinical Oncology)

ACTONEL (Risedronate Sodium) Tablet, Film Coated [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 17 Feb 2010 05:00:00 +0100

Updated Date: Feb 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))